Megestrol acetate for cachexia-anorexia syndrome. A systematic review
Abstract In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. The mechanism by which MA increases appetite is unknown, and its effectiveness for ano...
Saved in:
Main Authors: | Vicente Ruiz‐García (Author), Eduardo López‐Briz (Author), Rafael Carbonell‐Sanchis (Author), Sylvia Bort‐Martí (Author), José Luis Gonzálvez‐Perales (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2018-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dose‐dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta‐analysis
by: Sepide Talebi, et al.
Published: (2024) -
Adjuvant chemotherapy of megestrol acetate in advanced breast cancer: A meta-analysis
by: Yanping Shui, et al.
Published: (2015) -
Characterizing the Drug-Release Enhancement Effect of Surfactants on Megestrol-Acetate-Loaded Granules
by: Gábor Katona, et al.
Published: (2022) -
Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome
by: Naoki eFujitsuka, et al.
Published: (2014) -
A Review of Olanzapine in the Treatment of Cancer Anorexia-Cachexia Syndrome
by: Ivy O. Poon, et al.
Published: (2024)